|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
*
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
DE68927904T2
(de)
|
1988-09-01 |
1997-09-04 |
Takeda Chemical Industries Ltd |
Fumagillol-Derivate
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
EP0387650B1
(en)
|
1989-03-06 |
1993-03-31 |
Takeda Chemical Industries, Ltd. |
6-epifumagillols, production and use thereof
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
US6017954A
(en)
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(enExample)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
ATE205092T1
(de)
|
1992-01-30 |
2001-09-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
|
|
ATE153854T1
(de)
|
1992-12-16 |
1997-06-15 |
Takeda Chemical Industries Ltd |
Stabile pharmazeutische zubereitung mit fumagillolderivaten
|
|
JP3260378B2
(ja)
|
1995-03-27 |
2002-02-25 |
サノフィーサンテラボ |
腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用
|
|
CA2234401A1
(en)
|
1995-10-11 |
1997-04-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular permeation inhibitor
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
AU3968597A
(en)
|
1996-08-02 |
1998-02-25 |
Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
|
WO1998056372A1
(en)
|
1997-06-09 |
1998-12-17 |
Massachusetts Institute Of Technology |
TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
|
|
WO1999039702A2
(en)
|
1997-10-31 |
1999-08-12 |
Children's Medical Center Corporation |
Method for regulating size and growth of vascularized normal tissue
|
|
US6242494B1
(en)
|
1998-05-01 |
2001-06-05 |
Abbott Laboratories |
Substituted β-amino acid inhibitors of methionine aminopeptidase-2
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
KR100357541B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-데메톡시 푸마질롤 유도체 및 그 제조방법
|
|
KR100293504B1
(ko)
|
1998-06-05 |
2001-07-12 |
김윤 |
서방형전립선염치료제조성물
|
|
JP2000116337A
(ja)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
ペットフード
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
EE200100558A
(et)
|
1999-04-28 |
2002-12-16 |
Aventis Pharma Deutschland Gmbh |
Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
|
|
WO2001024796A1
(en)
|
1999-10-01 |
2001-04-12 |
Smithkline Beecham Corporation |
1,2,4-triazole derivatives, composition, process of making and methods of use
|
|
EP1274424A4
(en)
|
2000-04-12 |
2003-09-17 |
Smithkline Beecham Corp |
CONNECTIONS AND PROCEDURE
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
AR030631A1
(es)
|
2000-09-29 |
2003-08-27 |
Abbott Lab |
Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
CN1505617A
(zh)
|
2000-11-01 |
2004-06-16 |
������˹ҩƷ��˾ |
作为Met-AP2抑制剂的肽
|
|
US20040116495A1
(en)
|
2001-03-29 |
2004-06-17 |
Marino Jr. Joseph P. |
Compounds and methods
|
|
US20020183242A1
(en)
|
2001-04-11 |
2002-12-05 |
Jack Henkin |
Peptide antiangiogenic drugs
|
|
WO2003027104A1
(en)
|
2001-09-27 |
2003-04-03 |
Idrtech Inc. |
Fumagillol derivatives and preparing method thereof
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
KR100451485B1
(ko)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
WO2003107090A1
(en)
|
2002-06-12 |
2003-12-24 |
Silicon Optix, Inc. |
Automatic keystone correction system and method
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US7030262B2
(en)
|
2002-08-06 |
2006-04-18 |
Abbott Laboratories |
3-Amino-2-hydroxyalkanoic acids and their prodrugs
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US7491718B2
(en)
|
2002-10-08 |
2009-02-17 |
Abbott Laboratories |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
|
CA2550873A1
(en)
|
2003-12-29 |
2005-07-21 |
Praecis Pharmaceuticals, Inc. |
Inhibitors of methionine aminopeptidase-2 and uses thereof
|
|
KR100552043B1
(ko)
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
푸마질롤 유도체를 포함하는 비만치료용 조성물
|
|
AU2005259864A1
(en)
|
2004-06-30 |
2006-01-12 |
Combinatorx, Incorporated |
Methods and reagents for the treatment of metabolic disorders
|
|
WO2006010498A2
(en)
|
2004-07-28 |
2006-02-02 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
CN101142210A
(zh)
|
2005-01-26 |
2008-03-12 |
株式会社钟根堂 |
烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物
|
|
FR2886855B1
(fr)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
|
|
US20070078172A1
(en)
|
2005-06-16 |
2007-04-05 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
EP2170402B1
(en)
|
2007-06-26 |
2015-03-25 |
Children's Medical Center Corporation |
Metap-2 inhibitor polymersomes for therapeutic administration
|
|
JP5557746B2
(ja)
*
|
2007-11-28 |
2014-07-23 |
メルサナ セラピューティックス，インク． |
生体適合性生分解性フマギリンアナログ複合体
|
|
US8299067B2
(en)
*
|
2008-03-27 |
2012-10-30 |
Versitech Limited |
5-demethoxyfumagillol and derivatives thereof
|
|
NZ590732A
(en)
|
2008-07-18 |
2012-09-28 |
Zafgen Inc |
Methods of treating an overweight or obese subject using fumagillin
|
|
EP2350012B1
(en)
|
2008-10-06 |
2017-06-28 |
The Johns Hopkins University |
Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
|
|
CA2741683C
(en)
|
2008-10-24 |
2016-03-22 |
Wake Forest University |
Platinum acridine anti-cancer compounds and methods thereof
|
|
WO2010065881A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
US8642650B2
(en)
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
WO2010065877A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
WO2010065879A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
WO2011044506A2
(en)
|
2009-10-09 |
2011-04-14 |
Zafgen Corporation |
Sulphone compounds and methods of making and using same
|
|
WO2011085201A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Fumagillol type compounds and methods of making and using same
|
|
US8815309B2
(en)
|
2010-01-08 |
2014-08-26 |
Zafgen, Inc. |
Methods of treating a subject with benign prostate hyperplasia
|
|
WO2011088055A2
(en)
|
2010-01-12 |
2011-07-21 |
Zafgen Corporation |
Methods and compositions for treating cardiovascular disorders
|
|
US20130266578A1
(en)
|
2010-04-07 |
2013-10-10 |
Thomas E. Hughes |
Methods of treating an overweight subject
|
|
US20130210821A1
(en)
|
2010-05-27 |
2013-08-15 |
James E. Vath |
Methods for Treating Obesity
|
|
KR20130043207A
(ko)
|
2010-07-22 |
2013-04-29 |
자프겐 인크. |
트리시클릭 화합물 및 이의 제조 및 사용 방법
|
|
CA2814413A1
(en)
|
2010-10-12 |
2012-04-19 |
Zafgen, Inc. |
Sulphonamide compounds and methods of making and using same
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
WO2012064928A1
(en)
|
2010-11-10 |
2012-05-18 |
Zafgen Corporation |
Methods and compositions for treating thyroid hormone related disorders
|
|
US20140011870A1
(en)
|
2010-11-29 |
2014-01-09 |
Zafgen, Inc. |
Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor
|
|
WO2012074968A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
|
|
JP2013543899A
(ja)
|
2010-11-29 |
2013-12-09 |
ザフゲン，インコーポレイテッド |
６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
|
|
BR112013018771A2
(pt)
|
2011-01-26 |
2019-09-17 |
Zafgen Inc |
compostos de tetrazol e métodos para fazer e usar os mesmos
|
|
BR112013023056A2
(pt)
|
2011-03-08 |
2018-10-09 |
Zafgen Inc |
derivados de oxaespiro [2,5] octano e análogos
|
|
AU2012253757B2
(en)
|
2011-05-06 |
2017-04-13 |
Zafgen Inc. |
Partially saturated tricyclic compounds and methods of making and using same
|
|
EP2705036B1
(en)
|
2011-05-06 |
2015-08-12 |
Zafgen Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
WO2012154679A1
(en)
|
2011-05-06 |
2012-11-15 |
Zafgen Corporation |
Tricyclic pyrazole sulfonamide compounds and methods of making and using same
|
|
US9090640B2
(en)
|
2011-09-02 |
2015-07-28 |
Ulrich Bierbach |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|
|
EP2763671A2
(en)
|
2011-10-03 |
2014-08-13 |
Zafgen, Inc. |
Methods of treating age related disorders
|
|
MX2014008705A
(es)
|
2012-01-18 |
2015-02-05 |
Zafgen Inc |
Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
|
|
KR20140112565A
(ko)
|
2012-01-18 |
2014-09-23 |
자프겐 인크. |
삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
|
|
AU2013259760A1
(en)
|
2012-05-07 |
2014-11-20 |
Zafgen, Inc. |
Polymorphic salt of the oxalate salt of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol and methods of making and using same
|
|
MX2014013599A
(es)
|
2012-05-08 |
2015-05-11 |
Zafgen Inc |
Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
|
|
KR20150016534A
(ko)
*
|
2012-05-09 |
2015-02-12 |
자프겐 인크. |
푸마지롤형 화합물 및 이의 제조 및 사용 방법
|
|
MX362391B
(es)
|
2013-03-14 |
2019-01-15 |
Zafgen Inc |
Métodos de tratamiento de enfermedad renal y otros trastornos.
|
|
AR105671A1
(es)
*
|
2015-08-11 |
2017-10-25 |
Zafgen Inc |
Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
|